Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand? DOI Open Access
Patricia Giuliani,

Chiara Simone,

Giorgia Febo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 9778 - 9778

Published: Sept. 10, 2024

Like most tumors, glioblastoma multiforme (GBM), the deadliest brain tumor in human adulthood, releases extracellular vesicles (EVs). Their content, reflecting that of origin, can be donated to nearby and distant cells which, by acquiring it, become more aggressive. Therefore, study EV-transported molecules has very important. Particular attention been paid EV proteins uncover new GBM biomarkers potential druggable targets. Proteomic studies have mainly performed “bottom-up” mass spectrometry (MS) analysis EVs isolated different procedures from conditioned media cultured biological fluids patients. Although a great number dysregulated identified, translation these findings into clinics remains elusive, probably due multiple factors, including lack standardized for isolation/characterization their proteome. Thus, it is time change research strategies adopting, addition harmonized selection techniques, MS methods aimed at identifying selected tumoral protein mutations and/or isoforms post-translational modifications, which deeply influence behavior. Hopefully, data integrated with those other “omics” disciplines will lead discovery pathways novel therapies.

Language: Английский

Unraveling the role of the P2X7 receptor in cancer radioresistance: Molecular insights and therapeutic implications DOI

Seyedeh Nasibeh Mousavikia,

Maryam Moghaddam Matin,

Mohammad Taghi Bahreyni Tossi

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Journal Year: 2025, Volume and Issue: 1872(3), P. 119910 - 119910

Published: Jan. 29, 2025

Language: Английский

Citations

0
The epigenetic mechanisms involved in the treatment resistance of glioblastoma DOI Open Access

Aanya Shahani,

Hasan Slika, Ahmed Elbeltagy

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Glioblastoma (GBM) is an aggressive malignant brain tumor with almost inevitable recurrence despite multimodal management surgical resection and radio-chemotherapy. While several genetic, proteomic, cellular, anatomic factors interplay to drive promote treatment resistance, the epigenetic component remains among most versatile heterogeneous of these factors. Herein, landscape GBM refers a myriad modifications processes that can alter gene expression without altering genetic code cancer cells. These encompass DNA methylation, histone modification, chromatin remodeling, non-coding RNA molecules, all which have been found be implicated in augmenting tumor’s behavior driving its resistance therapeutics. This review aims delve into underlying interactions mediate this role for each components. Further, it discusses two-way relationship between heterogeneity plasticity, are crucial effectively treat GBM. Finally, we build on previous characterization explore specific targets investigated development promising therapeutic agents.

Language: Английский

Citations

0
Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies DOI Creative Commons
Martina Bedeschi, Elena Cavassi, Antonino Romeo

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 385 - 385

Published: March 8, 2025

Glial-origin brain tumors, particularly glioblastomas (GBMs), are known for their devastating prognosis and characterized by rapid progression fatal outcomes. Despite advances in surgical resection, complete removal of the tumor remains unattainable, with residual cells driving recurrence that is resistant to conventional therapies. The GBM microenviroment (TME) significantly impacts treatment response. In this review, we explore emerging role purinergic signaling, especially P2X7 receptor (P2X7R). Due its unique characteristics, it plays a key offers potential therapeutic strategy through TME modulation. We discuss also P2X4 (P2X4R) as promising target. Overall, targeting signaling approach overcoming current limitations.

Language: Английский

Citations

0
Significant Changes in Low-Abundance Protein Content Detected by Proteomic Analysis of Urine from Patients with Renal Stones After Extracorporeal Shock Wave Lithotripsy DOI Creative Commons

Elena Carestia,

Fabrizio Di Giuseppe,

Mohammad Kazemi

et al.

Biology, Journal Year: 2025, Volume and Issue: 14(5), P. 482 - 482

Published: April 27, 2025

Extracorporeal shock wave lithotripsy (ESWL), although a highly effective method for the treatment of kidney stones, can cause significant damage. Since urinary protein composition directly reflects function, proteomic analysis this fluid may be useful to identify changes in levels induced by patient exposure ESWL as sign To end, we collected urine samples from 80 patients with nephrolithiasis 2 h before and 24 after ESWL, which were concentrated subsequently processed commercially available enrichment extract low-abundance proteins. These then separated 2D electrophoresis analyzed approach. A large number proteins identified being related inflammatory, fibrotic, antioxidant processes some them confirmed Western blot analysis. Therefore, further experimental confirmation is needed, our results demonstrate that significantly influences low profile nephrolithiasis. Notably, among proteins, matrix metalloproteinase 7, alpha1-antitrypsin, clusterin, well dimethyl arginine amino hydrolase ab-hydrolase, play an important role putative biomarkers monitoring management ESWL-induced renal

Language: Английский

Citations

0
Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand? DOI Open Access
Patricia Giuliani,

Chiara Simone,

Giorgia Febo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 9778 - 9778

Published: Sept. 10, 2024

Like most tumors, glioblastoma multiforme (GBM), the deadliest brain tumor in human adulthood, releases extracellular vesicles (EVs). Their content, reflecting that of origin, can be donated to nearby and distant cells which, by acquiring it, become more aggressive. Therefore, study EV-transported molecules has very important. Particular attention been paid EV proteins uncover new GBM biomarkers potential druggable targets. Proteomic studies have mainly performed “bottom-up” mass spectrometry (MS) analysis EVs isolated different procedures from conditioned media cultured biological fluids patients. Although a great number dysregulated identified, translation these findings into clinics remains elusive, probably due multiple factors, including lack standardized for isolation/characterization their proteome. Thus, it is time change research strategies adopting, addition harmonized selection techniques, MS methods aimed at identifying selected tumoral protein mutations and/or isoforms post-translational modifications, which deeply influence behavior. Hopefully, data integrated with those other “omics” disciplines will lead discovery pathways novel therapies.

Language: Английский

Citations

0